Astodrimer - Starpharma

Drug Profile

Astodrimer - Starpharma

Alternative Names: 3% w/w SPL7013 Gel; Astodrimer sodium; BRI-7013; Fleurstat BV; SPL-7013; VivaGel; VivaGel®BV

Latest Information Update: 11 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biomolecular Research Institute
  • Developer Starpharma
  • Class Antibacterials; Antivirals; Dendrimers; Peptides
  • Mechanism of Action Anion transport protein modulators; Surface antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Registered Bacterial vaginosis
  • Phase I/II Herpes simplex virus infections; HIV infections
  • Research Human papillomavirus infections; Zika virus infection

Most Recent Events

  • 09 Jul 2018 Astodrimer is available for licensing in North America as of 09 Jul 2018. http://www.starpharma.com/
  • 09 Jul 2018 US FDA accepts NDA for astodrimer for Bacterial vaginosis (Recurrent, Prevention, Treatment) for Priority review
  • 27 Jun 2018 Astodrimer licensed to Mundipharma in European Union, Commonwealth of Independent States and rest of Latin America
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top